Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine

BioNTech has axed a Phase 2 trial of its personalized mRNA cancer vaccine just a week after Moderna and Merck had breakout success for their own approach in a much different cancer setting. BioNTech said ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 28 August →